# Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus

> **NCT06787586** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Attovia Therapeutics Inc** · enrollment: 108 (actual)

## Conditions studied

- Normal Volunteers
- Atopic Dermatitis (AD)
- Atopic Eczema
- Chronic Pruritus

## Interventions

- **DRUG:** ATTO-1310
- **DRUG:** ATTO-1310 Placebo

## Key facts

- **NCT ID:** NCT06787586
- **Lead sponsor:** Attovia Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-14
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06787586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06787586, "Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06787586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*